Home Society Investing in Biotech Strategy Service Press review Newsletter Contacts Thanks to the decoding of DNA, scientists are now able to understand what are the rules of functioning of our body and what determines a particular disease. Biotechnologies relating to human health, agriculture and the environment will create a world market of the order of several hundred billion dollars in the near future. In the field of health alone, new biotech drugs already have a turnover of more than 130 billion dollars and in the special ranking of the ten best-selling drugs in the world, six come from biotech companies. We are living in the age of biotechnology! News Regeneron and Sanofi have announced the approval of Kevzara (22-05-2017) [...] Array BioPharma announces agreement with Merck (08-05-2017) [...] J. Lamarck: six reasons against the theory of the biotech sector in a bubble (16-06-2015) [...] Reflections on the descent of prices. Is it time to buy? (16-05-2014) [...] Biogen Idec Makes Large Donation of Hemophilia Drugs to Help Poor Nations (15-05-2014) [...] Press review See all news> Follow us: Twitter J. Lamarck SpA Via Anelli, 28 25015 Desenzano del Garda (BS) Italy Tel. +39.030.8362633 - Fax. +39.030.8362548 Registration number in the Brescia company register, tax code and VAT number 02684320233 - Share capital of Euro 120,000.00 iv